Stock BCAB BIOATLA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages BioAtla, Inc.

Equities

BCAB

US09077B1044

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
3.25 USD +2.85% Intraday chart for BioAtla, Inc. +27.95% +32.11%
03-27 HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating MT
03-26 Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioAtla, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
Sector Update: Health Care Stocks Advance in Afternoon Trading
BioAtla Rallies After CEO Buys 50,000 Shares
Bioatla Hosting Virtual R&D Day to Highlight Ba3071 Cab-Ctla-4 Phase 1 Data in Multiple Solid Tumor Types
Sector Update: Health Care Stocks Slipping Tuesday Afternoon
BioAtla Says Clinical Benefits, Safety Profile Support Further Evaluation of Potential Lung Cancer Therapy
BioAtla, Inc. Presents Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
Top Premarket Decliners
BioAtla, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
BioAtla, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Top Premarket Decliners
Viatris Projects Lower 2023 Revenue Despite Swinging to Fourth-Quarter Profit
BioAtla President Scott Smith to Leave; Appointed as CEO at Viatris
Bioatla, Inc. Announces Resignation of Scott Smith as President
BioAtla Says US FDA Approves Investigational New Drug Application for BA3182 to Treat Adenocarcinoma
Bioatla Announces FDA Clearance of Investigational New Drug Application for Ba3182, A Cab Epcamxcab-Cd3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
BioAtla Sees Dosing of First Patient in Mid-Stage Part 2 Study in Soft Tissue Cancer This Quarter
BioAtla Proposes Common Stock Offering of up to $100 Million
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BCAB Stock
  4. News BioAtla, Inc.
  5. Other languages